MA33936B1 - Antidotes pour anticoagulants - Google Patents
Antidotes pour anticoagulantsInfo
- Publication number
- MA33936B1 MA33936B1 MA35080A MA35080A MA33936B1 MA 33936 B1 MA33936 B1 MA 33936B1 MA 35080 A MA35080 A MA 35080A MA 35080 A MA35080 A MA 35080A MA 33936 B1 MA33936 B1 MA 33936B1
- Authority
- MA
- Morocco
- Prior art keywords
- anticoagulants
- antidote
- antidotes
- relates
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne des molécules d'anticorps contre des anticoagulants, en particulier le dabigatran, et leur utilisation en tant qu'antidotes de tels anticoagulants.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10151239 | 2010-01-20 | ||
US38391410P | 2010-09-17 | 2010-09-17 | |
PCT/EP2011/050749 WO2011089183A2 (fr) | 2010-01-20 | 2011-01-20 | Antidotes d'anticoagulants |
Publications (1)
Publication Number | Publication Date |
---|---|
MA33936B1 true MA33936B1 (fr) | 2013-01-02 |
Family
ID=42061991
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA35080A MA33936B1 (fr) | 2010-01-20 | 2011-01-20 | Antidotes pour anticoagulants |
Country Status (43)
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI513466B (zh) | 2010-01-20 | 2015-12-21 | Boehringer Ingelheim Int | 抗凝血劑解毒劑 |
ES2634098T3 (es) | 2011-01-14 | 2017-09-26 | The Regents Of The University Of California | Anticuerpos terapéuticos contra la proteína ROR-1 y procedimientos para el uso de los mismos. |
US20140050743A1 (en) * | 2011-01-19 | 2014-02-20 | Bayer Intellectual Property Gmbh | Binding proteins to inhibitors of coagulation factors |
JP2014515740A (ja) * | 2011-03-30 | 2014-07-03 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗凝固薬の解毒剤 |
AR089020A1 (es) | 2011-11-29 | 2014-07-23 | Perosphere Inc | Agentes de reversion anticoagulante |
CN105229033B (zh) | 2013-03-14 | 2019-04-23 | 拜尔健康护理有限责任公司 | 针对与肝素复合的抗凝血酶β的单克隆抗体 |
WO2015059159A1 (fr) * | 2013-10-25 | 2015-04-30 | Boehringer Ingelheim International Gmbh | Antidotes à des anticoagulants |
TW201623331A (zh) * | 2014-03-12 | 2016-07-01 | 普羅帝納生物科學公司 | 抗黑色素瘤細胞黏著分子(mcam)抗體類及使用彼等之相關方法 |
CN105223348A (zh) * | 2014-05-26 | 2016-01-06 | 北京九强生物技术股份有限公司 | 人抗凝血酶iii的胶乳增强免疫比浊法检测试剂盒 |
EP2980218A1 (fr) * | 2014-07-30 | 2016-02-03 | Rheinische Friedrich-Wilhelms-Universität Bonn | Complexe de thrombine aptamère à utiliser comme antidote à action directe sur les inhibiteurs de la thrombine |
EP3175245B1 (fr) * | 2014-07-31 | 2019-05-29 | Haemonetics Corporation | Détection et classification d'un anticoagulant à l'aide d'un test de coagulation |
US10300154B2 (en) | 2014-09-17 | 2019-05-28 | David R Elmaleh | Anticoagulant derivatives for cardiovascular imaging |
EP4205743A1 (fr) | 2014-12-31 | 2023-07-05 | Shenzhen Pharmacin Co., Ltd. | Composition pharmaceutique et son procédé de préparation |
US10449195B2 (en) | 2016-03-29 | 2019-10-22 | Shenzhen Pharmacin Co., Ltd. | Pharmaceutical formulation of palbociclib and a preparation method thereof |
US11879014B2 (en) | 2017-03-17 | 2024-01-23 | Tusk Therapeutics Ltd. | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody |
EA202091488A1 (ru) * | 2017-12-24 | 2020-09-23 | Нойл-Иммьюн Байотек, Инк. | Иммунокомпетентная клетка, которая экспрессирует молекулу клеточной поверхности, специфически распознающую человеческий мезотелин, il-7 и ccl19 |
JP2021515568A (ja) | 2018-03-13 | 2021-06-24 | タスク セラピューティクス リミテッド | 腫瘍特異的細胞枯渇のための抗cd25 |
WO2019217705A1 (fr) * | 2018-05-11 | 2019-11-14 | Proplex Technologies, LLC | Protéines de liaison et lymphocytes t de récepteur antigénique chimérique ciblant des granules de gasp-1 et leurs utilisations |
EP3873916A4 (fr) | 2018-10-29 | 2022-08-10 | Huahai US Inc. | Nouveaux composés dipeptidiques et leurs utilisations |
US20220175748A1 (en) | 2019-03-06 | 2022-06-09 | University Of Rochester | Anticoagulant compositions and uses thereof |
CN114306245A (zh) | 2020-09-29 | 2022-04-12 | 深圳市药欣生物科技有限公司 | 无定形固体分散体的药物组合物及其制备方法 |
TW202321311A (zh) * | 2021-08-02 | 2023-06-01 | 日商諾伊爾免疫生物科技股份有限公司 | 與scFv等之連接子結合的抗體 |
US11446286B1 (en) * | 2022-02-28 | 2022-09-20 | King Faisal University | Treatment of fungal infections using dabigatran etexilate |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6087380A (en) | 1949-11-24 | 2000-07-11 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
ATE87659T1 (de) | 1986-09-02 | 1993-04-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
KR0184860B1 (ko) | 1988-11-11 | 1999-04-01 | 메디칼 리써어치 카운실 | 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법) |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
ES2102007T3 (es) * | 1992-01-23 | 1997-07-16 | Merck Patent Gmbh | Proteinas de fusion de fragmentos de anticuerpo monomeras y dimeras. |
DE4203965A1 (de) | 1992-02-11 | 1993-08-12 | Max Planck Gesellschaft | Antidot fuer hirudin und synthetische thrombininhibitoren |
PT656946E (pt) | 1992-08-21 | 2001-12-28 | Univ Bruxelles | Imunoglobulinas desprovidas de cadeias leves |
DE69329974T2 (de) | 1992-12-04 | 2001-07-19 | Medical Research Council, London | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
NZ266838A (en) | 1993-06-03 | 1997-02-24 | Therapeutic Antibodies Inc | Treatment of patients with anti-tnfalpha antibody, antibody fragment |
AT404357B (de) | 1995-06-13 | 1998-11-25 | Immuno Ag | Prothrombin-derivate |
DE19605126A1 (de) | 1996-02-12 | 1997-08-14 | Basf Ag | Thrombinmuteine als Antidot für Thrombininhibitoren |
US6200955B1 (en) | 1996-06-11 | 2001-03-13 | Commonwealth Biotechnologies, Inc. | Heparin binding peptides |
GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
PE121699A1 (es) * | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | Heterociclos biciclicos disustituidos como inhibidores de la trombina |
JP4187277B2 (ja) | 1997-04-30 | 2008-11-26 | エンゾン ファーマシューティカルズ, インコーポレイテッド | グリコシル化し得る抗原結合単鎖タンパク質、それらの生成および使用 |
DE19729544A1 (de) * | 1997-07-10 | 1999-01-14 | Basf Ag | Ancrod spezifische monoklonale Antikörper, Antikörperfragmente, deren Mischung oder Derivate und deren Verwendung |
US6440417B1 (en) | 1998-11-06 | 2002-08-27 | Conjuchem, Inc. | Antibodies to argatroban derivatives and their use in therapeutic and diagnostic treatments |
US6624141B1 (en) | 1999-03-17 | 2003-09-23 | The Regents Of The University Of Michigan | Protamine fragment compositions and methods of use |
AU2001266557A1 (en) | 2000-04-12 | 2001-10-23 | Human Genome Sciences, Inc. | Albumin fusion proteins |
IL156955A0 (en) | 2001-01-17 | 2004-02-08 | Genecraft Inc | Binding domain-immunoglobulin fusion proteins |
US20040097547A1 (en) | 2001-04-16 | 2004-05-20 | Taveras Arthur G. | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
US20070031438A1 (en) * | 2001-12-10 | 2007-02-08 | Junghans Richard P | Antibodies as chimeric effector cell receptors against tumor antigens |
WO2003050531A2 (fr) | 2001-12-11 | 2003-06-19 | Algonomics N.V. | Procede d'affichage de boucles de domaines d'immunoglobuline dans differents contextes |
ES2263984T3 (es) | 2002-06-28 | 2006-12-16 | Domantis Limited | Ligandos doble-especificos con una vida media serica aumentada. |
EP3299393A1 (fr) | 2002-11-08 | 2018-03-28 | Ablynx N.V. | Anticorps à domaine unique dirigés contre le facteur alpha de la nécrose tumorale et leurs utilisations |
CN1845938B (zh) | 2003-06-30 | 2010-05-26 | 杜门蒂斯有限公司 | 多肽 |
BR122022001846B1 (pt) * | 2007-09-28 | 2022-12-27 | Portola Pharmaceuticals, Inc. | Uso de polipeptídeo de duas cadeias para preparo de medicamento para reduzir sangramento |
AR070141A1 (es) * | 2008-01-23 | 2010-03-17 | Glenmark Pharmaceuticals Sa | Anticuerpos humanizados especificos para el factor von willebrand |
NZ597359A (en) | 2009-08-24 | 2014-01-31 | Boehringer Ingelheim Int | Emergency interventions of active charcoal with dabigatran etexilate overdosing |
TWI513466B (zh) * | 2010-01-20 | 2015-12-21 | Boehringer Ingelheim Int | 抗凝血劑解毒劑 |
-
2011
- 2011-01-19 TW TW100102006A patent/TWI513466B/zh active
- 2011-01-19 AR ARP110100179A patent/AR079944A1/es active IP Right Grant
- 2011-01-20 RS RS20170195A patent/RS55683B1/sr unknown
- 2011-01-20 PE PE2012000997A patent/PE20121516A1/es active IP Right Grant
- 2011-01-20 CA CA2787566A patent/CA2787566A1/fr not_active Abandoned
- 2011-01-20 KR KR1020127019086A patent/KR101781787B1/ko active IP Right Grant
- 2011-01-20 ME MEP-2017-29A patent/ME02602B/fr unknown
- 2011-01-20 AP AP2012006242A patent/AP2012006242A0/xx unknown
- 2011-01-20 UA UAA201209779A patent/UA110470C2/ru unknown
- 2011-01-20 HU HUE11703410A patent/HUE032263T2/en unknown
- 2011-01-20 BR BR112012018021-5A patent/BR112012018021B1/pt active IP Right Grant
- 2011-01-20 EP EP11703410.8A patent/EP2525812B1/fr active Active
- 2011-01-20 WO PCT/EP2011/050749 patent/WO2011089183A2/fr active Application Filing
- 2011-01-20 MY MYPI2012002840A patent/MY162323A/en unknown
- 2011-01-20 NZ NZ599508A patent/NZ599508A/en unknown
- 2011-01-20 LT LTEP11703410.8T patent/LT2525812T/lt unknown
- 2011-01-20 SI SI201131156A patent/SI2525812T1/sl unknown
- 2011-01-20 PL PL11703410T patent/PL2525812T3/pl unknown
- 2011-01-20 UY UY0001033196A patent/UY33196A/es active IP Right Grant
- 2011-01-20 MA MA35080A patent/MA33936B1/fr unknown
- 2011-01-20 JP JP2012549355A patent/JP5575923B2/ja active Active
- 2011-01-20 EP EP16205771.5A patent/EP3195876A1/fr not_active Withdrawn
- 2011-01-20 PT PT117034108T patent/PT2525812T/pt unknown
- 2011-01-20 CN CN201180006616.4A patent/CN102711813B/zh active Active
- 2011-01-20 DK DK11703410.8T patent/DK2525812T3/en active
- 2011-01-20 ES ES11703410.8T patent/ES2614992T3/es active Active
- 2011-01-20 US US13/010,403 patent/US8486398B2/en active Active
- 2011-01-20 MX MX2012008360A patent/MX2012008360A/es active IP Right Grant
- 2011-01-20 AU AU2011208719A patent/AU2011208719C1/en active Active
- 2011-01-20 SG SG2012052445A patent/SG182552A1/en unknown
- 2011-01-20 EA EA201201016A patent/EA028371B1/ru active Protection Beyond IP Right Term
- 2011-01-20 GE GEAP201112836A patent/GEP20156341B/en unknown
-
2012
- 2012-04-19 ZA ZA2012/02876A patent/ZA201202876B/en unknown
- 2012-04-25 IL IL219427A patent/IL219427B/en active IP Right Grant
- 2012-07-18 TN TNP2012000366A patent/TN2012000366A1/en unknown
- 2012-07-23 CO CO12123109A patent/CO6571889A2/es active IP Right Grant
- 2012-08-14 EC ECSP12012105 patent/ECSP12012105A/es unknown
-
2013
- 2013-01-23 HK HK13101025.2A patent/HK1173957A1/xx unknown
- 2013-06-13 US US13/916,994 patent/US9034822B2/en active Active
-
2014
- 2014-07-02 JP JP2014136811A patent/JP2014210794A/ja active Pending
-
2015
- 2015-04-13 US US14/684,576 patent/US20150210778A1/en not_active Abandoned
-
2017
- 2017-03-22 CY CY20171100361T patent/CY1118875T1/el unknown
- 2017-04-14 HR HRP20170613TT patent/HRP20170613T1/hr unknown
- 2017-07-06 NL NL300882C patent/NL300882I2/nl unknown
- 2017-07-10 CY CY2017025C patent/CY2017025I1/el unknown
- 2017-07-10 FR FR17C1026C patent/FR17C1026I2/fr active Active
- 2017-07-10 LT LTPA2017021C patent/LTC2525812I2/lt unknown
- 2017-07-11 NO NO2017034C patent/NO2017034I1/no unknown
- 2017-07-12 LU LU00028C patent/LUC00028I2/fr unknown
- 2017-07-13 HU HUS1700030C patent/HUS1700030I1/hu unknown
-
2022
- 2022-08-12 NO NO2022036C patent/NO2022036I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA33936B1 (fr) | Antidotes pour anticoagulants | |
MA37538B1 (fr) | Anticorps et immunoconjugués anti-ly6e et procédés d'utilisation | |
MA43187A (fr) | Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations | |
EA201390145A1 (ru) | Конъюгаты, частицы, композиции и связанные с ними способы | |
MA35712B1 (fr) | Anticorps anti-htra1 et leurs procédés d'utilisation | |
MA47664A1 (fr) | Anticorps anti-c10orf54 et leurs utilisations | |
MA35009B1 (fr) | Cristaux d'anticorps anti-sclérotine et formulations de ceux-ci | |
MA35898B1 (fr) | Anticorps anti-lrp5 et leurs procédés d'utilisation | |
MA34978B1 (fr) | Antidotes pour anticoagulants | |
FR2983077B1 (fr) | Seringue | |
TN2015000050A1 (en) | Methods of treating a tauopathy | |
MA34488B1 (fr) | Composition pesticides | |
EP2569330A4 (fr) | Variants de la chlorotoxine, conjugués, et leurs méthodes d'utilisation | |
EA201590174A1 (ru) | Иммуноконъюгаты, содержащие анти-cd22 антитела | |
MA33208B1 (fr) | Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci | |
EA201590173A1 (ru) | Иммуноконъюгаты, содержащие антитела к cd22 | |
UA104005C2 (ru) | 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции | |
MA34722B1 (fr) | Méthodes et compositions pour l'immunothérapie de maladies neurales | |
MA38686A1 (fr) | Anticorps anti-acide téichoïque de la paroi cellulaire et conjugués associés | |
MA33551B1 (fr) | Anticorps anti-egfl1 humanises, et procedes d'utilisation correspondants | |
MA44550A1 (fr) | Anticorps anti-acide téichoique de la paroi cellulaire et conjugués associés | |
NZ701463A (en) | Anti-phytopathogenic composition | |
MA42166B1 (fr) | Seringue | |
MA37643A1 (fr) | Récipients | |
WO2012156665A3 (fr) | Procédés et compositions liés à la sensibilité plaquettaire |